Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Focused Fund median (28 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 26 Aug 2021 – 20 Aug 2026, limited by UTI Focused Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | UTI Focused Fund | Nifty 500 |
|---|---|---|
| 26 Aug 2021 | ₹100.00 | ₹100.00 |
| 25 Jan 2022 | ₹100.09 | ₹105.14 |
| 25 Jun 2022 | ₹92.08 | ₹94.44 |
| 24 Nov 2022 | ₹106.82 | ₹111.16 |
| 25 Apr 2023 | ₹103.64 | ₹106.02 |
| 23 Sep 2023 | ₹122.22 | ₹122.36 |
| 22 Feb 2024 | ₹139.12 | ₹143.79 |
| 23 Jul 2024 | ₹161.97 | ₹162.08 |
| 21 Dec 2024 | ₹156.24 | ₹158.22 |
| 22 May 2025 | ₹160.99 | ₹160.17 |
| 21 Oct 2025 | ₹169.12 | ₹168.42 |
| 21 Mar 2026 | ₹150.45 | ₹151.19 |
| 20 Aug 2026 | ₹169.82 | ₹166.68 |
| Metric | UTI · Direct NAV ₹16.99 Very High risk ★★★☆☆ | Category median Focused Fund · 28 funds |
|---|---|---|
| +2.76% | +5.84% | |
| +12.87% | +15.09% | |
| +11.21% | +13.35% | |
| — | +13.62% | |
| +11.21% | +15.49% | |
| +11.44% | — | |
| +16.11% | +16.73% | |
| — | +16.52% | |
| — | +16.05% | |
| Risk | ||
| 13.38% | 14.55% | |
| 0.48 | 0.57 | |
| 0.66 | 0.79 | |
| -19.32% | -34.05% | |
| Nifty 500 | — | |
| +0.96% | +3.16% | |
| 0.93 | 0.94 | |
| 100.2% | 104.9% | |
| 96.1% | 89.6% | |
| 1.03% | 1.06% | |
| ₹2,383Cr | ₹2,441Cr | |
| 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 60% | 32% | |
| Vishal Chopda | — | |
| 26 Aug 2021 | — | |
| 29 | — | |
| 53.3% | — | |
| 3.0% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.